Life Scientist > Health & Medical

Atomo wins Best In Show at MDEA

12 June, 2014 by Dylan Bushell-Embling

Atomo Diagnostics' HIV blood test, AtomoRapid HIV, has been named Best In Show at the Medical Design Excellence Awards.


NHMRC awards for excellence

12 June, 2014

This year's National Health and Medical Research Council's prizes for excellence in health and medical research have been announced.


Alchemia aims to report on mCRC trial in Q3

10 June, 2014 by Dylan Bushell-Embling

Alchemia (ASX:ACL) now expects top-line results from its phase III trial of HA-Irinotecan in colorectal cancer to be ready in Q3, and aims to file FDA and EMA submissions in 1H15.


Immunotherapy shows promise in treating brain cancer

05 June, 2014

Combining standard treatment for recurrent glioblastoma multiforme with immune-based therapies holds promise for patients with this aggressive disease.


Viralytics presents more strong Cavatak trial data

05 June, 2014 by Dylan Bushell-Embling

Viralytics (ASX:VLA) announced that Cavatak has to date generated an overall response rate of 26% during a phase II melanoma trial and has demonstrated synergy with mAb therapy during preclinical research.


Supporting Indigenous health

03 June, 2014

A $10 million philanthropic gift will be used to establish a Poche Centre for Indigenous Health at the University of Melbourne.


CVac boosts OS in second-remission ovarian cancer

03 June, 2014 by Dylan Bushell-Embling

Data from a phase II trial of Prima BioMed's (ASX:PRR) CVac show that the treatment has had a positive effect on overall survival in ovarian cancer patients in second-line remission.


Virax completes purchase of Pathway Oncology

02 June, 2014 by Dylan Bushell-Embling

Virax Holdings (ASX:VHL) has closed the deal to acquire Pathway Oncology, and with it an exclusive licence to a first-in-class cancer therapeutic candidate.


Sienna reagent and cancer biomarker registered with FDA

29 May, 2014

The US FDA has registered the lead product of Melbourne-based biotech company Sienna Cancer Diagnostics - the antibody SCD-A7.


Patient responds well to Patrys's PAT-SM6

29 May, 2014 by Dylan Bushell-Embling

A patient with relapsed multiple myeloma responded well to a combination of Patrys's (ASX:PAB) PAT-SM6 and a proteosome inhibitor, which bodes well for an upcoming trial.


Novogen to test SBPs in prostate cancer

27 May, 2014 by Dylan Bushell-Embling

Novogen (ASX:NRT) has identified a number of super-benzopyran (SBP) compounds with a potent effect against prostate cancer cells in vitro, and aims to trial the lead candidate in 2015.


Prima's US patent for CVac allowed

26 May, 2014 by Dylan Bushell-Embling

The US patent office has granted Prima BioMed a Notice of Allowance covering a patent application protecting cancer treatment candidate CVac.


IST raising $5m for cancer trial, ASX listing

21 May, 2014 by Dylan Bushell-Embling

Immune System Therapeutics (IST) has announced plans to place up to $5m in new shares, to raise funds for a phase IIb multiple myeloma trial and an ASX listing in the third quarter.


No link between vaccinations and autism

21 May, 2014

A comprehensive systematic review of childhood vaccinations has found no evidence of a link to the development of autism or autism spectrum disorders.


Budget delivers a mixed bag for science

16 May, 2014 by Susan Williamson

The federal government's first Budget delivers a mixed outcome for science, research and innovation.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd